Amyotrophic lateral sclerosis (ALS) is a progressive degenerative motor neuron disease involving the motor cortex, corticospinal tract, brainstem, and spinal anterior horn neurons.
1 The disease is uniformly fatal, although the clinical presentation and course are heterogeneous, with median survival times between 2 and 4 years.
2 Patients present most commonly with combined upper motor neuron (UMN) and lower motor neuron (LMN) features, although, earlier in the disease course, only UMN or LMN signs may be present. Although electromyography confirms LMN signs in ALS, UMN signs are solely assessed on clinical grounds that can delay diagnosis. This is due in part to the fact that UMN signs in ALS can be masked by LMN weakness and secondary hyporeflexia rather than hyperreflexia.
3 Riluzole, the only medication for ALS approved by the US Food and Drug Administration, has limited efficacy, extending average life expectancy by only 3 to 6 months.
4,5 Riluzole is postulated to modulate excitatory neurotransmission, although the exact in vivo pharmacologic actions are not well understood.
6